亚虹医药：CDE已完成APL-1702技术评审

Core Viewpoint - Yahui Pharmaceutical is accelerating the review and approval process for its drug APL-1702 after receiving technical review completion from the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - The CDE has completed the technical review of APL-1702 [1] - The company aims to expedite the listing approval process for APL-1702 [1]